Roche signs Hansoh Pharma oncology ADC collaboration with more than $15 billion in potential milestones

Roche and Hansoh Pharma have signed a major oncology licensing agreement involving antibody-drug conjugates, with more than $15 billion in potential milestone payments.

The collaboration covers a portfolio of ADC programmes targeting multiple cancers, including two existing programmes and potential additional projects, with Roche responsible for later-stage development and commercialisation outside Greater China.

Hansoh is eligible for $400 million upfront, $110 million on the first anniversary, more than $15 billion in contingent milestones and royalties, making the agreement one of the largest potential oncology licensing arrangements announced in 2026.

Field	Content
Article Type	Deals
Companies	Roche; Hansoh Pharma
Deal Type	Strategic collaboration and licensing agreement
Therapeutic Area	Oncology
Therapeutic Modality	Antibody-drug conjugates (ADCs)
Portfolio Scope	Two existing ADC programmes and potential additional projects
Upfront Payment	$400 million
First Anniversary Payment	$110 million
Potential Milestones	More than $15 billion in contingent milestone payments
Royalties	Additional royalties; rates not disclosed in supplied summary
Total Potential Consideration	More than $15.51 billion including upfront and first-anniversary payments; contingent milestones are not guaranteed
Licensed Territory	Outside mainland China, Hong Kong, Macau and Taiwan
Roche Responsibilities	Later-stage development and commercialisation in licensed territories
Hansoh Responsibilities	Collaboration on ADC programmes; detailed development responsibilities not confirmed in supplied summary
Development Stage	Individual programme stages not specified in supplied summary
What Happened	Roche and Hansoh Pharma entered a new oncology collaboration and licensing agreement covering a portfolio of antibody-drug conjugates.
Why It Matters	The partnership substantially expands Roche's access to investigational ADC programmes and strengthens its oncology development pipeline.
Strategic Rationale	Roche gains rights to multiple oncology assets while Hansoh receives substantial upfront funding and opportunities for future milestones and royalties.
Previous Collaboration	This agreement is distinct from the companies' earlier ADC collaboration.
Key Takeaway	The agreement provides Hansoh with $400 million upfront and potentially more than $15 billion in milestones; most of the headline value is contingent.
What to Watch	Programme disclosures, clinical development progress, milestone achievements and regulatory submissions.
Primary Source	Hansoh Pharma
Primary Source URL	https://www.hspharm.com/news/news-detail-513518.htm
Relevant Date	19 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com